Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Aprea Therapeutics ( (APRE) ).
On January 28, 2026, Aprea Therapeutics entered into a securities purchase agreement with new and existing healthcare-focused institutional investors and company insiders for a $5.6 million private placement of 6,288,857 shares of common stock (or pre-funded warrants) and accompanying common stock purchase warrants, priced at the Nasdaq “at-the-market” minimum price of $0.89 per unit, with warrants exercisable at $0.765 per share for two years. The financing, expected to close on or about January 30, 2026, is structured with standard ownership caps, no price-reset or anti-dilution ratchets beyond customary adjustments, and registration rights for resale, and is accompanied by amended restrictions on future equity issuance; Aprea plans to use the net proceeds for general corporate purposes and research and development, including adding patients to key dose levels in its ongoing Phase 1 ACESOT-1051 study of APR-1051, where on January 29, 2026 it also reported a first unconfirmed partial response, a development that could support more robust dose optimization data and potentially strengthen the program’s value and clinical trajectory.
The most recent analyst rating on (APRE) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Aprea Therapeutics stock, see the APRE Stock Forecast page.
Spark’s Take on APRE Stock
According to Spark, TipRanks’ AI Analyst, APRE is a Neutral.
APRE scores low primarily due to weak financial performance (ongoing losses and cash burn despite being debt-free) and a bearish technical setup (price below key moving averages with negative MACD). Valuation is constrained by negative earnings and no dividend, partially offset by moderately positive corporate updates and financing extending cash runway.
To see Spark’s full report on APRE stock, click here.
More about Aprea Therapeutics
Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments that exploit specific vulnerabilities in tumor cells while minimizing damage to healthy tissue. Its lead programs include APR-1051, an oral small-molecule WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development for advanced solid tumors such as ovarian, endometrial, colorectal, prostate, and breast cancers.
Average Trading Volume: 72,809
Technical Sentiment Signal: Sell
Current Market Cap: $5.8M
For an in-depth examination of APRE stock, go to TipRanks’ Overview page.